An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly integrating cutting-edge international research with Chinese ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

"We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

This cancer is more common in Black women than in White women. Incidence rates have increased by more than1% per year since the mid-2000s. Over the past decade, the rate increased by 0.6% per year in ...

CEO John Houston emphasized that Arvinas is nearing key milestones, including the first Phase 3 topline data for vepdegestrant (vepdeg) from the VERITAC-2 trial expected in Q1 2025. He noted that this ...

NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...